Get started
Author

Marina Nechaeva

Observed names: M Nechaeva, M. N. Nechaeva, M. Nechaeva, M.N. Nechaeva
ORCID: 0009-0005-4128-2643
Observed ORCID: 0009-0005-4128-2643
OpenAlex ID: A5108379227
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
2021 · Ahmet Sezer, Saadettin Kilickap, et al. · The Lancet · 845
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
2019 · Cathy Eng, Tae Won Kim, et al. · The Lancet Oncology · 596
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
2022 · Miranda Gogishvili, Tamar Melkadze, et al. · Nature Medicine · 344
PDF
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
2020 · Markus Moehler, Mikhail Dvorkin, et al. · Journal of Clinical Oncology · 236
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial
2024 · Fred Saad, Egils Vjaters, et al. · Journal of Clinical Oncology · 199
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
2023 · Tamta Makharadze, Miranda Gogishvili, et al. · Journal of Thoracic Oncology · 130
PDF
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
2023 · Mustafa Özgüroğlu, Saadettin Kilickap, et al. · The Lancet Oncology · 123
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice
2021 · Sergey Tjulandin, Lev Demidov, et al. · European Journal of Cancer · 64
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
2018 · Vera Gorbunova, J. Thaddeus Beck, et al. · British Journal of Cancer · 57
PDF
Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).
2020 · Markus H. Moehler, Mikhail Dvorkin, et al. · Journal of Clinical Oncology · 52
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1
2025 · Saadettin Kilickap, Ana Baramidze, et al. · Journal of Thoracic Oncology · 50
PDF
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
2025 · Amit M Oza, Alla Lisyanskaya, et al. · The Lancet Oncology · 31
Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3
2023 · Tamta Makharadze, Ruben G. W. Quek, et al. · Cancer · 19
PDF
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial
2024 · Ana Baramidze, Tamta Makharadze, et al. · Lung Cancer · 17
PDF
1Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase III study
2021 · Rebecca Kristeleit, Alla Lisyanskaya, et al. · Gynecologic Oncology · 12
LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial
2022 · M. Özgüroğlu, S. Kilickap, et al. · Annals of Oncology · 10
PDF
Efficacy and safety of empegfilgrastim, a novel pegylated G-CSF: Results of complete analysis after 4 cycles of myelosuppressive chemotherapy in phase III double-dummy randomized clinical study.
2015 · Olga Filon, Marina Nechaeva, et al. · Journal of Clinical Oncology · 6
OA01.03 Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
2021 · S. Kilickap, A. Sezer, et al. · Journal of Thoracic Oncology · 5
PDF
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
2019 · Vera Gorbunova, J. Thaddeus Beck, et al. · British Journal of Cancer · 3
PDF
Phase II trial (BCD-100-2/MIRACULUM) of the novel PD-1 inhibitor (BCD-100) in patients with advanced melanoma.
2019 · Sergey Fogt, Mariia Shustova, et al. · Journal of Clinical Oncology · 3
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial
2026 · Ana Baramidze, Tamta Makharadze, et al. · Journal of Thoracic Oncology · 1
Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors
2022 · Hanny Al-Samkari, Caglayan Geredeli, et al. · Blood · 1
Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.
2018 · Vera Gorbunova, Thaddeus Beck, et al. · Journal of Clinical Oncology · 1
Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1
2026 · Marina Chiara Garassino, Ana Baramidze, et al. · JTO Clinical and Research Reports
Results of a multicenter international study on the efficacy and safety of Remaxol in patients with drug-induced liver injury during antitumor therapy
2025 · R.A. Zukov, M.V. Kopp, et al. · P A Herzen Journal of Oncology
Works count: 26
Citation count: 2,805
H-index: 14
I10-index: 16
Year
Topic
Type